Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Global Blood Therapeutics, Inc. (GBT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
32.80+0.85 (+2.66%)
At close: 04:00PM EDT
33.00 +0.20 (+0.61%)
After hours: 04:08PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close31.95
Open32.04
Bid26.08 x 3200
Ask34.00 x 1200
Day's Range31.58 - 33.76
52 Week Range21.65 - 40.69
Volume1,247,896
Avg. Volume1,531,629
Market Cap2.135B
Beta (5Y Monthly)1.11
PE Ratio (TTM)N/A
EPS (TTM)-4.86
Earnings DateAug 01, 2022 - Aug 05, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est59.68
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GBT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Global Blood Therapeutics, Inc.
    Technical Assessment: Bearish in the Intermediate-TermMarket sentiment remains in the tank and the stock market simply cannot put together a decent rally. The National Association of Active Investment Managers (NAAIM) exposure index has fallen back to 20%, an extremely low equity exposure and a very bearish stance toward equities. This is the second time the index has dropped to 20% in the past six weeks. The seven-week average of exposure has fallen to 30%, the lowest since the pandemic low, as well as in 2015, 2011, and 2008/2009.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
Advertisement
Advertisement